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Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for
acute ischemic stroke, but its use is limited to the first hours after stroke onset due to an
increased risk of hemorrhagic transformation over time resulting in enhanced brain injury. In
this review we discuss the role of matrix metalloproteinases (MMPs) in blood-brain barrier
(BBB) disruption as a consequence of ischemic stroke. MMP-9 in particular appears to play
an important role in tPA-associated hemorrhagic complications. Reactive oxygen species
can enhance the effects of tPA on MMP activation through the loss of caveolin-1 (cav-1), a
protein encoded in the cav-1 gene that serves as a critical determinant of BBB permeability.
This review provides an overview of MMPs’ role in BBB breakdown during acute ischemic
stroke. The possible role of MMPs in combination treatment of acute ischemic stroke is
also examined.
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INTRODUCTION
Stroke is the third leading cause of death in industrialized countries
(Lo et al., 2003) and the most frequent cause of permanent dis-
ability in adults worldwide (Donnan et al., 2008). Acute ischemic
stroke is the most common form of stroke and results from sudden
blood vessel occlusion by a thrombus or embolism, resulting in an
almost immediate loss of oxygen and glucose to the cerebral tissue.
Although different mechanisms are involved in the pathogenesis of
stroke, increasing evidence shows that ischemic injury and inflam-
mation account for its pathogenic progression (Muir et al., 2007).
Cerebral ischemia initiates cascades of pathological events, includ-
ing vasogenic edema, disruption of the blood-brain barrier (BBB),
intracranial hemorrhage (ICH),astroglial activation,and neuronal
death. This ultimately causes irreversible neuronal injury in the
ischemic core within minutes of the onset (Dimagl et al., 1999).
Despite advances in understanding the pathophysiology of
cerebral ischemia, treatment options for acute ischemic stroke
Abbreviations: AJ, adherens junction; APC, activated protein C; BBB, blood-brain
barrier; BM, basement membrane; BMDC, bone marrow-derived cells; BMEC,
brain microvascular endothelial cells; cav-1, caveolin-1; dKO, double knockout; EC,
endothelial cell; ECM, extracellular matrix; HT, hemorrhagic transformation; ICH,
intracranial hemorrhage; KO, knockout; l-NAME, N(G) -nitro-l-arginine methyl
ester; LPS, lipopolysaccharide; LRP, lipoprotein receptor-related protein; MCAO,
middle cerebral artery occlusion; MMP, metalloproteinase; NF-κB, nuclear factor
kappa beta; PAR1, protease-activated receptor 1; ROS, reactive oxygen species;
SB-3CT, (2-[[(4-phenoxyphenyl) sulfonyl] methyl]-thiirane); SOD2, superoxide
dismutase; TIMP, tissue inhibitor of MMP; TJ, tight junction; tPA, tissue type
plasminogen activator; WT, wild-type; ZO, zona occludins.
remain very limited (Donnan et al., 2008). Intravenous recom-
binant tissue plasminogen activator (tPA) remains the only FDA-
approved thrombolytic therapy for reestablishing blood flow and
salvaging brain tissue after acute ischemic stroke (Lijnen and
Collen, 1987; National Institute of Neurological Disorders and
Stroke rt-PA Stroke Study Group, 1995). By degrading fibrin clots,
tPA acts as a thrombolytic agent through the activation of plas-
minogen to plasmin (Lijnen and Collen, 1987). Although tPA
administered within 4.5 h or less of symptom onset improves the
functional outcome in patients (Miller et al., 2012; Wardlaw et al.,
2012), it induces a 10-fold increase of symptomatic intracranial
hemorrhage (ICH) (National Institute of Neurological Disorders
and Stroke rt-PA Stroke Study Group, 1995). Furthermore, delayed
reperfusion with tPA beyond 3 h is associated with an increased
risk of hemorrhagic transformation (HT) with enhanced brain
injury (Clark et al., 1999). Moreover, tPA may cause injury to the
BBB by activating matrix metalloproteinases (MMPs) (Wang et al.,
2003). Thus, the therapeutic application of tPA is limited to spe-
cific clinical settings (National Institute of Neurological Disorders
and Stroke t-PA Stroke Study Group, 1997). There is a pressing
need to identify new combination therapies that can prevent tPA-
associated ICH as well as extend the time window for thrombolysis
without reducing its benefits.
Recent studies suggest that tPA adverse effects are mediated
through MMPs, a family of >20 zinc-dependent enzymes that
increase BBB permeability by degrading components of the extra-
cellular matrix (ECM) and tight junctions (TJ) in endothelial
cells (ECs) (Lapchak et al., 2000; Lijnen, 2001; Briasoulis et al.,
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2012). Increased expression and activation of MMPs plays a pivotal
role in thrombolysis-mediated BBB leakage and edema, resulting
in intracranial hemorrhage (Lapchak et al., 2000; Sumii and Lo,
2002). Reactive oxygen species (ROS) and its signaling pathways
can enhance the effects of tPA on MMP activation (Harada et al.,
2012). In this review we provide an overview of the role of MMPs
in BBB breakdown during acute ischemic stroke and the potential
for MMP inhibition in the treatment of stroke.
STRUCTURAL COMPONENTS OF THE BBB/NEUROVASCULAR
UNIT
The BBB is a dynamic interface between the peripheral circula-
tion and the CNS. It controls the influx and efflux of biological
substances needed for the brain metabolic processes, as well as for
neuronal function. Thus, the functional and structural integrity of
the BBB is vital in maintaining brain homeostasis.
The structure of the BBB has been discussed in reviews else-
where (Sandoval and Witt, 2008; Abbott et al., 2010). Briefly, the
anatomical substrate of the BBB is the cerebral microvascular
endothelium, which together with the closely associated astrocytes,
pericytes, neurons, and the ECM, constitute a“neurovascular unit”
that is essential for the health and function of the CNS (del Zoppo,
2009). Cell–cell interactions in the neurovascular unit form the
basis for brain function. Dysfunctional signaling in the neurovas-
cular unit underlies the basis for disease. Alterations in microvessel
integrity may have other effects within the neurovascular unit that
affect neuronal function. The mechanisms of neurovascular unit
response to stroke are not fully understood. However, any fully
effective stroke therapy must include both prevention of cell death
as well as repair of integrated neurovascular function.
The microcapillary endothelium is composed of TJs and
adherens junctions (AJs). Both TJs and AJs act to restrict perme-
ability across the endothelium (Bazzoni and Dejana, 2004). TJs are
continuous membrane strands located at the apical site between
brain ECs, which consist of transmembrane proteins (junctional
adhesion molecule-1, claudins, and occludin), and cytoplasmic
proteins (zonula occludens-1 to -3) linked to the actin cytoskeleton
(Morita et al., 1999). Among the claudin family members, claudin-
5 has been shown to be a major cell adhesion molecule of BBB
TJs (Yang and Rosenberg, 2011). The structure and function of
TJ proteins can be regulated by alternating their expression and/or
distribution at the BBB during ischemic stroke. Phosphorylation is
a major regulatory mechanism of both transmembrane and acces-
sory proteins at the TJ (Staddon et al., 1995; Stuart and Nigam,
1995; Sakakibara et al., 1997; Yamamoto et al., 2008). Disruption
of BBB TJ by disease or drugs can lead to impaired BBB function,
compromising CNS function (Hawkins and Davis, 2005). There-
fore, understanding exactly how BBB TJ might be vulnerable to
damage may lead to precise, effective prevention and treatment of
neurological diseases.
Adherens junctions are ubiquitous in the vasculature, medi-
ating the adhesion of ECs to each other. The AJs are mainly
composed of vascular endothelial VE-cadherin, a Ca2+-regulated
protein that facilitates cell to cell adhesion by forming a continu-
ous belt near the apical end of the junctional cleft (Vincent et al.,
2004). Although disruption of AJs at the BBB can lead to increased
permeability, it is primarily the TJ that confers low paracellular
permeability and high electrical resistance (Abbruscato and Davis,
1999). AJs may play an important role in the localization and
stabilization of the TJs. Endothelial VE-cadherin upregulates TJ
protein claudin-5, suggesting a direct regulation of TJ integrity by
AJ proteins (Taddei et al., 2008).
MATRIX METALLOPROTEINASES
Matrix metalloproteinases, also called matrixins, comprise a fam-
ily of enzymes that cleave protein substrates based on a conserved
mechanism involving activation of a site-bound water molecule
by a Zn2+ ion. MMPs consist of 23 distinct proteases in humans
(24 in mouse). Excreted MMPs are generally classified according
to their substrate specificity, leading to four classes: the collage-
nases (MMP-1, -8, and -13), the gelatinases (MMP-2 and -9),
the stromelysins (MMP-3, -10, and -11) and a heterogenous
group containing matrilysin (MMP-7), metallo-elastase (MMP-
12), enamelysin (MMP-20), endometase (MMP-26), and epilysin
(MMP-28) (Klein and Bischoff, 2011). An alternate classification
arranges the MMPs according to their domain structure (Stern-
licht and Werb, 2001). Most of the MMPs are synthesized as
inactive latent enzymes. Conversion to the active enzyme is gen-
erally mediated by activator systems that include plasminogen
activator or the pro-hormone convertase, furin. Although the cat-
alytic domain of MMPs is structurally similar, there are many
differences in substrate specificity, cellular and tissue localization,
membrane binding and regulation, making this a versatile family
of enzymes with a multitude of physiological functions, which are
not fully understood. Essentially, all members of the MMP family
have been linked to disease development, notably to cancer metas-
tasis, chronic inflammation with ensuing tissue damage, as well
as to neurological disorders (for review see Klein and Bischoff,
2011).
Matrix metalloproteinase activity is regulated by a group of
endogenous proteins called tissue inhibitor of metalloproteinases
(TIMPs), which bind to active and alternative sites of activated
MMP (Malemud, 2006). Four homologous TIMPs (TIMPs 1–4)
have been identified to date (21–30 kDa in size) (Gomez et al.,
1997). In a combined laser microdissection and protein array
study, TIMP-1 was upregulated in the infarcted tissue in human
brain after stroke compared to healthy controls (Cuadrado et al.,
2009). In a mouse model of focal cerebral ischemia (30 min of
middle cerebral artery occlusion, MCAO), the deletion of the
TIMP-1 gene resulted in increased MMP-9 protein expression
and gelatinolytic activity, and was accompanied by exacerbated
BBB disruption, neuronal apoptosis, and ischemic injury when
compared to wild-type (WT) animals (Fujimoto et al., 2008).
Interestingly, TIMP-2 knockout (KO) mice also had a leakier BBB
compared to WT animals, but no increase in MMP-9 expres-
sion or exacerbation of neuronal loss when compared to WT
mice (Fujimoto et al., 2008). By contrast, when transgenic mice
overexpressing the human TIMP-1 gene under the control of the
metallothionein-1 promoter were subjected to controlled corti-
cal impact, reduced 24-h MMP-9 levels and a less leaky BBB, as
well as decreased brain tissue damage at 7 days post-trauma were
observed compared to control animals (Tejima et al., 2009). In a
model of transient 2-h focal cerebral ischemia, MMP-9 levels were
lower in TIMP-1 KO mice compared to WTs. Correspondingly,
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BBB leakage was ameliorated by TIMP-1 overexpression, and 24-h
infarction volumes were also reduced. These observations collec-
tively suggest that MMPs could represent the potential targets for
pharmacological intervention in stroke and the inhibition of their
activity may actually have therapeutic effects (Figure 1) (Maier
et al., 2006).
The injured brain has various cell types that can express MMPs,
including resident and infiltrating inflammatory cells. However,
the brain regions and cellular sources of expression differ for the
specific MMPs, as well as the type, severity, and duration of injuries
(Cheng et al., 2006). MMPs can also be released from invading
leukocytes (Chou et al., 2011). In particular, MMP-8 is known as
the “neutrophil collagenase” (Hasty et al., 1986).
ROLE IN BBB DISRUPTION
Disruption of the BBB during focal cerebral ischemia/reperfusion
injury has long been considered to follow a biphasic time course.
Morphologically, BBB opening correlates with a redistribution
of the TJ and AJ proteins from the plasma membrane to the
cytoplasm as well as reorganization of the endothelial actin
cytoskeleton. The extent of BBB disruption is associated with the
type, severity, and duration of ischemic insults. The molecular
mechanisms underlying BBB opening are not fully understood,
although several MMPs are believed to regulate BBB permeability
and function during ischemic stroke (Mun-Bryce and Rosenberg,
1998).
The expression of MMPs in the adult brain is very low to unde-
tectable, but clinical and experimental studies have shown that
several MMPs are upregulated and activated after ischemic stroke
(Lee et al., 2007; McColl et al., 2008). MMPs disrupt the BBB
by degrading the TJ proteins and basal lamina proteins, thereby
leading to BBB leakage, leukocyte infiltration, brain edema, and
hemorrhage. Evidence suggests that MMP-2 and MMP-9 play dif-
ferent roles in BBB disruption during ischemic stroke. MMP-2 KO
does not provide neuroprotection in mouse models of permanent
and transient MCAO (Asahi et al., 2001b). Consistently, in vitro
FIGURE 1 | Mechanisms in MMP activation leading to degradation
of extracellular matrix and blood-brain barrier disruption/
hemorrhage. Acute stroke may lead to vascular endothelial cell injury
causing the release of proinflammatory cytokines and free radicals at the
neurovascular unit activating MMPs. tPA administration may likewise
induce MMPs through the LRP, PAR1, and PDGRF-α pathways. MMP
activation is inhibited by several agents including imatinib, activation
protein C (APC), cilostazol, melatonin, BB-94, GM6001, fasudil, AHA,
NYX-059, and edaravone (Table 2). LRP, lipoprotein receptor-related
protein; MMP, matrix metalloproteinase; PAR1, protease-activated
receptor 1; tPA, tissue type plasminogen activator. Figure modified from
Yamashita and Abe (2011).
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data show that MMP-2 is not toxic to neurons in hippocampal
slice preparations (Cunningham, 2005). In contrast, MMP-9 KO
provides strong neuroprotection in the same animal models, and
in vitro MMP-9 is toxic to neurons in hippocampal slice prepa-
rations and in cultured primary cortical neurons (Asahi et al.,
2000b). In support of these data, a clinical study (Lucivero et al.,
2007) reported an increase in plasma MMP-2 only in patients with
lacunar (mild) stroke early (within 12 h) and this was related to
better outcome. In contrast, an increase in plasma MMP-9 was
observed later (at day 7) and related to more severe stroke.
Matrix metalloproteinases are thought to have beneficial roles
in stroke recovery. Shortly after an ischemic insult, a cascade of
events is initiated in an attempt to repair the damage, a process
similar to that found in wound healing (National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study Group,
1995; Wardlaw et al., 2012). Following injury, blood vessels are
dependent on the plasminogen activator system and on MMPs
for their regeneration (Suzuki et al., 2009). It may be that a bal-
anced level of MMP activity is important for vascular remodeling
after ischemic brain injury (Yang and Rosenberg, 2011). Therefore,
extended inhibition of MMPs, especially through the use of broad-
spectrum inhibitors, might prove deleterious (National Institute
of Neurological Disorders and Stroke rt-PA Stroke Study Group,
1995; Donnan et al., 2008).
MMP-2 (GELATINASE A)
Matrix metalloproteinase-2 is one of the two described human
gelatinases in the MMP family, named for their ability to prote-
olytically degrade gelatine (denatured collagen) (see Table 1 for
a list of MMPs and their putative roles in acute ischemic stroke).
MMP-2 is ubiquitously expressed as a 72-kDa proenzyme and
subject to extensive glycosylation (Klein and Bischoff, 2011).
A study provided indirect evidence that MMP-2 played a key
role in initial opening of the BBB after cerebral ischemia (Rosen-
berg et al., 1998). In a rat model of transient MCAO, the initial
opening of the BBB occurred as early as 3 h after reperfusion and
increased activation of MMP-2 correlated with the early opening
of the BBB and the degradation of the TJ proteins claudin-5 and
occludin in both cerebral hemispheres (Rosenberg et al., 1992;
Yang et al., 2007). Experimental data clearly demonstrated an
increase in MMP-2 at 3 h, along with increased expression of
the MMP-2 activators, MT1-MMP and furin. A synthetic MMP
inhibitor (BB-1101) blocked the increase in brain MMP-2 levels,
but it did not have any effect on stroke lesion size at 48 h after
MCAO and had significant adverse effects on neurologic function
in rats at 3 and 4 weeks after MCAO (Rosenberg et al., 1992, 1998;
Yang et al., 2007). In contrast, direct injection of MMP-2 into the
rat brain resulted in the disruption of the BBB with subsequent
hemorrhage, and this effect was inhibited by co-administration of
TIMP-2 (Rosenberg et al., 1992). Thus, the early degradation of TJ
proteins seems to be associated with a marked increase in MMP-2
in the early phase of ischemia.
Suofu et al. (2012) recently assessed the effects of MMP-2 KO,
MMP-9 KO, and MMP-2/9 double KO (dKO) in protecting against
mechanical reperfusion-induced HT and other brain injuries after
the early stages of cerebral ischemia in mice of the same genetic
background. Both MMP-2 and MMP-9 specifically attack the type
IV collagen, laminin, and fibronectin, which are the major com-
ponents of the basal lamina around the cerebral blood vessels.
MCAO was performed and reperfusion was started at 1 or 1.5 h
after onset of MCAO. Mice were sacrificed 8 h later. Both pro-
and active-MMP-2 and MMP-9 levels were significantly elevated
in the early ischemic brain. After the early stages of ischemia and
reperfusion, the hemorrhagic incidence was reduced in the cortex
of MMP-2 KO mice. The hemorrhagic volume was also signifi-
cantly decreased in the cortexes of MMP-2 and/or -9 KO mice.
In the basal ganglia, MMP-2 KO and MMP-2/9 dKO mice dis-
played a remarkable decrease in hemorrhagic volume, but MMP-9
deletion did not protect against hemorrhage. MMP-2 and/or -9
KO mice displayed significantly decreased infarction volume in
Table 1 | MMPs and their putative role in acute ischemic stroke.
MMP Putative role
MMP-1 (collagenase-1) Preferentially cleaves type III collagen. Upregulated in infracted tissue. Limited studies
MMP-2 (gelatinase A) Attacks major components of the basal lamina around the cerebral blood vessels including type IV collagen, laminin, and
fibronectin. May contribute to infarction and hemorrhagic volume
MMP-3 (stromelysin-1) Degrades the extracellular matrix proteins fibronectin, denatured collagen, laminin, and proteoglycans. Plays a key role in the
initial opening of the BBB after stroke and the development of hemorrhagic transformation, particularly with tPA treatment
MMP-8 (collagenase-2) Preferentially cleaves type I collagen. Similar to MMP-1, is upregulated in infracted tissue and studies are limited
MMP-9 (gelatinase B) Attacks major components of the basal lamina including type IV collagen, laminin, and fibronectin. Plays a key role in the
delayed opening of the BBB after stroke especially in states of systematic inflammation. Also implicated in the development
of hemorrhagic transformation particularly with tPA treatment
MMP-10 (stromelysin-2) Disables thrombin-activatable fibrinolysis inhibitor, thereby enhancing tPA-induced fibrinolysis. May hasten reperfusion time
and limit infarction volume
MMP-13 (collagenase-3) Preferentially cleaves type II collagen. Functions may mirror MMP-9
BBB, blood-brain barrier; MMP, matrix metalloproteinase; tPA, tissue plasminogen activator.
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both the cortex and striatum, in addition to improved neurologi-
cal function. The results suggested that MMP-2 deficiency as well
as MMP-2 and MMP-9 double deficiency were more protective
than MMP-9 deficiency alone against HT after the early stages of
ischemia and reperfusion.
MMP-3 (STROMELYSIN-1)
Matrix metalloproteinase-3 (stromelysin-1) was first described in
1985 as a 51-kDa protein secreted by rabbit fibroblasts (Chin et al.,
1985). MMP-3 could be distinguished from collagenases by the
inability to degrade type I collagen. The substrate specificity of
MMP-3 is broad and MMP-3 has been found to degrade many
ECM proteins including fibronectin,denatured collagens (gelatin),
laminin, and proteoglycans (Klein and Bischoff, 2011).
Matrix metalloproteinase-3 appears to play an important role
in ICH induced by tPA treatment of ischemic stroke in mice. Using
the MCAO model, Suzuki et al. (2007) demonstrated that defi-
ciency of the stromelysin-1 (MMP-3) gene, but not the MMP-9
gene, in mice reduced the increased risk of ICH caused by tPA treat-
ment. In addition, administration of the broad-spectrum MMP
inhibitor GM6001 after tPA treatment significantly reduced ICH in
WT, but had no effect in MMP-3-deficient mice (Table 2). Further-
more, using a mouse stroke model, tPA treatment induced MMP-3
expression selectively in ECs damaged by ischemia. This suggests
that MMP-3 might be involved in degradation of the blood ves-
sel barrier and contribute to ICH. Although MMP-9 expression
was also significantly increased at the ischemic areas of the brain,
the amount and the distribution were comparable in mice with
and without tPA treatment. These data with gene-deficient mice
suggest that MMP-3 is relatively more important than MMP-9 for
the increased ICH induced by tPA treatment of ischemic stroke
in mice. In a combined laser microdissection and protein array
study, Cuadrado et al. (2009) found MMP-3 upregulated in the
infarcted tissue in human brain after stroke, along with several
other MMPs and TIMP-2. MMP-9 and TIMP-2 were amplified in
brain microvessels while MMP-10 was notably increased in neu-
rons of the ischemic brain but not in healthy areas. MMP-3 gene
polymorphisms were associated with ischemic stroke but not ICH
in the Korean population (Kim et al., 2012).
The mechanism underlying MMP-3 induction by tPA appears
to involve the low-density lipoprotein receptor-related protein
(LRP)/nuclear factor kappa-B (NF-κB) pathway. LRP, a member of
the lipoprotein receptor family, is a scavenger receptor that binds
a variety of biologic ligands, including tPA (Herz and Strickland,
2001). In the brain, LRP is found in neurons and perivascular
astrocytes (Polavarapu et al., 2007). In vitro, tPA induces MMP-3
in cultured murine brain ECs, and this effect is prevented by inhi-
bition of either LRP or the NF-κB activation (Suzuki et al., 2009).
The involvement of the LRP/NF-κB pathway was also reported in
the induction of MMP-3 by tPA under ischemic stress. In addi-
tion, the increase in both ICH and the induction of MMP-3 by
tPA was suppressed by treatment with RAP, suggesting that ICH
caused by tPA could be suppressed by LRP inhibition. LRP pro-
duction is reported to be upregulated in ECs exposed to ischemia,
and elevated LRP levels have been implicated in the increased ICH
risk associated with delayed tPA treatment. This implies that the
Table 2 | Drugs that can attenuate tPA-related hemorrhagic transformation of ischemic stroke.
Drug Proposed mechanism Model and reference
Imatinib (PDGFR-α antagonist) Inhibits PDGFR-α activity Mouse MCAO (Su et al., 2008)
Activated protein C (APC) Inhibits the tPA-PAR1-MMP-9 pathway Mouse and Rat MCAO (Cheng et al., 2006)
Cilostazol (phosphodiesterase III inhibitor) Inhibits MMP-9 activity Mouse MCAO (Ishiguro et al., 2010)
Rat MCAO (Choi et al., 2002)
Human trial (Lee et al., 2003)
Mouse MCAO (Nonaka et al., 2009)
Melatonin Inhibits MMP-9 activity Mouse MCAO (Chen et al., 2006)
BB-94 (MMP-9 inhibitor) Inhibits MMP-9 activity Rat MCAO (Pfefferkorn and Rosenberg, 2003)
Fasudil (rho kinase inhibitor) Inhibits MMP-9 activity Mouse MCAO (Ishiguro et al., 2012)
Minocycline (broad-spectrum tetracycline antibiotic) Inhibits MMP-9 activity Human trial (Switzer et al., 2011)
Human trial (Fagan et al., 2010)
GM6001 Inhibits MMP-3>MMP-9 activity Mouse MCAO (Suzuki et al., 2007)
AHA (p-aminobenzoyl-gly-pro-d-leu-d-ala-hydroxamate;
broad-spectrum MMP inhibitor)
Broad-spectrum MMP inhibitor Rat MCAO (Copin et al., 2011)
NXY-059 Scavenges free radicals Rat MCAO (Lapchak et al., 2002)
Rat MCAO (Green and Ashwood, 2005)
Edaravone Scavenges free radical Rat MCAO (Yamashita et al., 2009)
MCAO, middle cerebral artery occlusion; MMP, matrix metalloproteinase; tPA, tissue plasminogen activator.
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tPA/LRP/MMP-3 pathway may be a suitable target for develop-
ing strategies to improve the therapeutic efficacy of tPA in acute
ischemic stroke.
Matrix metalloproteinase-3 (stromelysin-1) has also been
shown to mediate BBB opening during neuroinflammation (Gur-
ney et al., 2006). After intracerebral injection of lipopolysaccharide
(LPS),MMP-3 KO mice showed less degradation of the TJ proteins
(claudin-5, occludin, laminin-alpha-1) together with reduced neu-
trophil infiltration when compared with WT mice (Gurney et al.,
2006). In the rat transient MCAO model, brain MMP-3 is acti-
vated as determined by the cleavage of the cerebral matrix agrin,
an MMP-3 substrate (Sole et al., 2004).
MMP-9 (GELATINASE B)
Matrix metalloproteinase-9 (gelatinase B), first described in neu-
trophils in 1974 (Sopata and Dancewicz, 1974), is expressed as
a 92-kDa proenzyme, which can be activated to the 83-kDa
mature enzyme. Among MMPs, MMP-9 is the most widely studied
enzyme in acute ischemic stroke. In particular, MMP-9 activity is
significantly elevated in human brain tissue and serum after stroke
(Clark et al., 1997; Montaner et al., 2001; Horstmann et al., 2003;
Switzer et al., 2011) as well as in animal stroke models begin-
ning at 12 h after permanent MCAO [54]. High plasma MMP-9
concentrations in the acute phase of a cerebral infarction is con-
sidered to be independent predictor of HT in all stroke subtypes
(Planas, 2001; Castellanos et al., 2003). MMP-9 has been shown to
degrade TJ proteins (claudin-5, occludin, ZO-1) in cultured brain
ECs (Chen et al., 2009) and in animal models of focal cerebral
ischemia (Yang et al., 2007; McColl et al., 2008). Aberrant MMP-9
proteolytic activity degrades not only TJ proteins but also basal
membrane proteins (e.g., fibronectin, laminin, collagen, and oth-
ers). This degradation is associated with an in increase in BBB
permeability, resulting in brain infarction, edema, and HT in both
animal models (Lee et al., 2007; Rosenberg and Yang, 2007; Yang
et al., 2007) and in human stroke patients (Gasche et al., 1999;
Castellanos et al., 2003; Lo, 2008). Moreover, cerebral infarct size
is reduced in mice deficient in MMP-9 or after treatment with
MMP inhibitor; this effect was associated with reduced degra-
dation of the MMP-9 substrate ZO-1 as compared to WT mice
(Asahi et al., 2000b, 2001a; Jiang et al., 2001). Early (day 1) MMP-
9 inhibition reduced infarction of day 14; however, benefit was
lost when the treatment was delayed until day 3. Stroke pathology
was exacerbated when administration was delayed until day 7 (Lo,
2008).
In contrast to MMP-2, which plays a key role in the initial open-
ing of the BBB after cerebral ischemia (see above), experimental
studies suggest that MMP-9 appears to be more important in the
second, delayed opening of the BBB after ischemic stroke (Adib-
hatla and Hatcher, 2008). In a rat model of transient MCAO, the
initial opening at 3 h correlated with increased brain MMP-2 lev-
els. In contrast, the second, delayed opening (maximal opening at
48 h) appeared to correlate with brain MMP-9 levels (maximally
elevated at 48 h) (Rosenberg et al., 1998). An increase in plasma
MMP-9 appears later, at day 7, and is correlated to more severe
patient strokes (Lucivero et al., 2007).
There is controversy regarding timing of brain MMP-9 expres-
sion and activation after ischemic stroke. In the rat transient
MCAO model, Planas (2001) show that MMP-9 is induced and
activated from 4 h to 4 days. In the mouse permanent MCAO
model, Gasche et al. (1999) show induced expression and activa-
tion of MMP-9 in the ischemic brain with increased permeability
as early as 2–4 h after ischemia. More recently, Demir et al. (2012)
reported that plasma MMP-9 levels substantially increased dur-
ing the acute period of ischemic stroke and were correlated with
disease severity and infarct volume in patients with stroke. These
studies suggest that MMP inhibition could have a beneficial effect
on the outcome of stroke but the effect will depend on the timing
of treatment to the stage of brain injury (Lo, 2008).
A recent review of the literature concerning MMP-9 and stroke
suggests that MMP-9 is a possible marker for acute ischemic stroke
(Ramos-Fernandez et al., 2011). This review revealed that higher
MMP-9 values were significantly correlated with larger infarct vol-
ume, severity of stroke, and worse functional outcome. There
were significant differences in MMP-9 levels between patients
with acute ischemic stroke and healthy control subjects. More-
over, MMP-9 was a predictor for the development of ICH in
patients treated with thrombolytic therapy. MMP-9 level was
significantly increased after stroke onset, with the level correlat-
ing with infarct volume, stroke severity, and functional outcome
(Ramos-Fernandez et al., 2011). Clinical studies have shown a
correlation between plasma MMP-9 levels and the rate of HT in
human stroke (Montaner et al., 2001; Castellanos et al., 2007).
Montaner et al. (2003) reported that a high level of plasma MMP-9
expression in stroke patients could predict HT after thrombolysis.
Recently, Demir et al. (2012) reported that plasma MMP-9 level
substantially increased during the acute period of ischemic stroke
and correlated with the severity of the disease and infarct volume
in patients with acute ischemic stroke. A substrate of MMP-9,
fibronectin, has also been reported to be a useful biomarker for
predicting HT (Castellanos et al., 2007).
Defining the precise role of plasma MMP-9 after ischemic
stroke will have important diagnostic implications for stroke and
help in the development of therapeutic strategies aimed at modu-
lating plasma MMP-9. Recently, it was shown that MMP-9 mRNA
concentration was almost three times higher in non-survival
patients compared to survival patients with acute stroke (Graham
et al., 2012); therefore, MMP-9 mRNA was a predictor of poor out-
come and mortality in stroke. Nevertheless, there is no significant
association between MMP-9 genetic variations or MMP-9 expres-
sion and HT occurrence after tPA treatment in stroke patients
(Fernandez-Cadenas et al., 2012).
Although MMP-9 is detectable in the brain after stroke, its
cellular source remains controversial. Endothelium, glia, and neu-
rons have been shown to display MMP-9 immunoreactivity after
ischemia. However, since MMP-9 functions as a protease after
being secreted from cells, the location of MMP-immunoreactivity
does not necessarily reflect the cells releasing MMP-9 (Wang et al.,
2009). Experimental data indicate that brain microvascular ECs
(BMECs) and infiltrating leukocytes (most likely neutrophils) are
key cellular sources of brain MMP-9 at least in the early phase
(within 24 h) after focal cerebral ischemia (Justicia et al., 2003;
McColl et al., 2008; Jin et al., 2010). Gidday et al. (2005) used
chimeric mice with MMP-9 KO and WT mice to demonstrate that
leukocytes are the major source of MMP-9 in the ischemic brain
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at 24 h following 2 h MCAO. By immunostaining and microdis-
section, clinical data confirm that microvessel endothelium and
infiltrating neutrophils are the major source of the increased brain
MMP-9 after ischemic and hemorrhagic stroke in humans (Rosell
et al., 2006). In contrast, Harris et al. (2005) failed to detect an
impact on MMP-9 levels from neutrophil depletion in ischemic
rat brain at 24 h after 3-h MCAO. Thus, infiltrating leukocytes
may not be the sole source of MMP-9 in the ischemic brain at later
reperfusion times.
There are temporal and spatial changes of MMP-9 within the
cells of the neurovascular unit after stroke. In a rat model of
transient MCAO, most of the MMP-9 activities co-localized with
brain microvessel ECs within 24 h, but at 7–14 days the MMP-9
signal shifted to the periphery of the cortical infarction and was
mainly associated with neurons and astrocytes (Zhao et al., 2006).
This redistribution likely reflects multiphasic roles of MMP-9 in
ischemic stroke. Inhibition of MMP-9 during the late phase (7–
14 days) after stroke has been shown to reduce the number of
neurons and new vessels, and that correlated with increased brain
injury and impaired functional recovery. Thus, it has been noted
that blocking MMPs at a badly chosen time in non-target cell types
may result in unwanted side effects (Zlokovic, 2006).
In several peripheral organs, MMP-9 derived from bone
marrow-derived cells (BMDC) is functionally significant (Wang
et al., 2009). BDMC have also been suggested to be an important
source of MMP-9 in the brain after ischemia (Gidday et al., 2005;
McColl et al., 2008). Results from experiments using bone mar-
row chimera indicate that BMDC are the major cellular source of
MMP-9 detectable in the ischemic brain after 90 min of MCAO
and 1 h of reperfusion, which is consistent with previous findings.
In addition, MMP-9 released from BMDC contributes to BBB dys-
function at 1 h after reperfusion and subsequent infarct formation
at 24 h.
There is evidence indicating that specific inhibition of MMP
activity during stroke onset or immediately following brain injury
improves neurological outcomes (Table 2). Murata et al. reported
that minocycline, a broad-spectrum MMP inhibitor, could reduce
neuronal cell death after ischemia and extend the thrombolytic
time window (Murata et al., 2008). Moreover, MMP-9 KO can sta-
bilize the BBB by preventing degradation of the TJ protein ZO-1
(Asahi et al., 2001a). A recent clinical trial indicates that minocy-
cline can lower plasma MMP-9 levels, even at 72 h after stroke, and
improve neurological outcomes in acute ischemic stroke patients
treated with tPA (Switzer et al., 2011).
Cui et al. (2012) recently used an embolic cerebral
ischemia mouse model to evaluate (4-phenoxyphenylsulfonyl)
methylthiirane (referred to as SB-3CT), the first mechanism-
based selective and potent MMP inhibitor selective for gelatinases
(Brown et al., 2000). Active gelatinases bind to SB-3CT and cat-
alyze the opening of the thiirane ring in the molecule. The resultant
species generated within the active site of the enzyme affords
tight binding between the inhibitor and the enzyme. SB-3CT pre-
vents proteolysis of the ECM basement membrane (BM) laminin
and protects neurons from focal cerebral ischemia (Gu et al.,
2005). Most importantly, significant therapeutic benefit can be
observed for up to 6 h after initial injury. Cui et al. demonstrated
MMP-9 activation and neurovasculature impairment in stroke and
showed the ability of SB-3CT to inhibit MMP-9 activity in vivo,
which resulted in maintenance of laminin, antagonism of peri-
cyte contraction and loss, and preservation of laminin-positive
pericytes and ECs. Repeated dose administration of SB-3CT for
7 days offered beneficial results. In contrast, delayed treatment
with the broad-spectrum MMP inhibitors FN-439 (day 3 or 7)
and BB-94 (day 7) significantly worsened infarct volumes (Zhao
et al., 2006). Thus, SB-3CT rescued neurons from apoptosis and
prevented ICH. Selective targeting of MMP-9 antagonizes disrup-
tion of the neurovascular unit and protects against brain dam-
age and vessel constriction. Taken together, these results strongly
indicate that the thiirane class of gelatinase selective inhibitors
holds great promise as therapeutic agents for the treatment of
stroke.
Although MMP-9 inhibition or KO can attenuate proteolysis of
BBB (Lijnen, 2001; Harada et al., 2012), more recent studies sug-
gest its possible role in neurovascular regeneration, especially in
the delayed phase of cerebral ischemia (Bazzoni and Dejana, 2004).
Following injury, blood vessels are dependent on the plasminogen
activator system and on MMPs for their regeneration. For exam-
ple, Zhao et al. (2006) showed that delayed inhibition of MMPs
by broad-spectrum inhibitors is detrimental during the ischemic
recovery stage 7 days after cerebral ischemia, diminishing brain
repair in mice, and attenuating neurovascular regeneration in the
penumbra. Thus, successful anti-stroke therapies require selective
inhibition of aberrant activity without altering the physiological
function of MMPs, such as their roles in axonal growth, synaptic
plasticity, and vascular remodeling following stroke (Mun-Bryce
and Ga, 1998; Malemud, 2006; Adibhatla and Hatcher, 2008;
Taddei et al., 2008; Yang and Rosenberg, 2011).
Several studies suggest MMP-9 may play a more prominent
role in BBB disruption during ischemic stroke under clinical con-
ditions linked to elevated systemic inflammation. Experimental
data have shown that systemic inflammation increases neutrophil
infiltration into the ischemic brain, thus altering the kinetics of the
BBB TJ disruption after experimental stroke (McColl et al., 2008).
These studies demonstrate that infiltrating neutrophils are the pri-
mary source of increased (fivefold) MMP-9 activity in the ischemic
brain of mice challenged with interleukin-1β (IL-1β) at 4, 8, or 24 h
after focal cerebral ischemia. A transformation from transient to
sustained BBB disruption caused by enhanced neutrophil-derived
MMP-9 is a critical mechanism underlying the exacerbation of
ischemic brain injury by IL-1β-induced systemic inflammation.
This inflammatory state results in a sustained disruption of the TJ
protein (claudin-5) and enhanced disruption of the cerebrovascu-
lar basal lamina protein (collagen-IV) (McColl et al., 2008). The
poor clinical outcome in stroke patients with elevated systemic
inflammatory status may stem from this mechanism.
MMP-10 (STROMELYSIN-2)
In addition to MMP-2/-3/-9, MMP-10 (stromelysin-2) may also
play an active role in mediating BBB disruption during ischemic
stroke. MMP-10,which has 82% sequence homology with MMP-3,
is secreted as a 53-kDa proenzyme and is activated to a 47-
kDa mature protease. The physiological function of MMP-10 is
poorly understood, with only a handful of publications attempt-
ing characterization of this protease. MMP-10 has been linked
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to inflammatory/thrombotic processes and vascular integrity, but
whether MMP-10 could have a profibrinolytic effect and represent
a promising thrombolytic agent is unknown. The effect of MMP-
10 on fibrinolysis was studied in vitro and in vivo in MMP-10
KO mice using two different murine models of arterial thrombo-
sis, laser-induced carotid injury and ischemic stroke (Orbe et al.,
2011). In vitro, it was shown that MMP-10 was capable of enhanc-
ing tPA-induced fibrinolysis. This was done via a mechanism that
disabled the thrombin-activatable fibrinolysis inhibitor. In vivo,
active recombinant human MMP-10 reversed delayed fibrinoly-
sis after photochemical carotid injury in MMP-10 KO mice. In a
thrombin-induced stroke model, the reperfusion and infarct size
in sham or tPA-treated animals were much worse in MMP-10 KO
mice. In this model, administration of active MMP-10 to WT ani-
mals significantly reduced blood reperfusion time and infarct size
to the same extent as tPA and was associated with shorter bleeding
time and no intracranial hemorrhage. This benefit was not seen
in thrombin-activatable fibrinolysis inhibitor-deficient mice, sug-
gesting thrombin-activatable fibrinolysis inhibitor inactivation as
one of the mechanisms involved in the MMP-10 profibrinolytic
effect.
MMP-13 (COLLAGENASE-3) AND OTHERS
Matrix metalloproteinase-13 (collagenase-3) is the latest human
collagenase described in the literature. This enzyme exhibits pref-
erence toward cleavage of type II collagen, effectively completing
the substrate spectrum of the collagenases. Collagenase-3 was first
cloned from breast cancer tissue in 1994 (Freije et al., 1994). This
MMP has been thoroughly studied in aggressive cancer as a bio-
marker of tumor progression (Balbin et al., 1999). In all cases,
high expression of MMP-13 seems to be related to the aggres-
siveness of the tumor. In addition, MMP-13 plays an important
role in bone turnover, and this enzyme has been linked to vari-
ous bone-related diseases (Burrage et al., 2006), making selective
MMP-13 inhibitors attractive therapeutic compounds. MMP-13
has also been shown to be involved in tissue injury after stroke
(Heim-Riether et al., 2009). Only one earlier study has attempted
to measure MMP-13 in human stroke within the first 12 h of
symptoms as compared with a healthy control group, but no dif-
ference was found (Horstmann et al., 2003). In contrast, Rosell
et al. (2005) investigated the blood levels of several MMPs in
stroke patients with MCAO who received thrombolytic therapy.
High levels of both MMP-9 and MMP-13 were detected in the
hyperacute phase of stroke and were correlated with an increase
in diffusion-weighted imaging lesions within the first 24 h. A
positive correlation was also found between these two metallopro-
teinases. Thus, both MMP-9 and MMP-13 are involved in tissue
injury and cell death, counteracting the benefits of thrombolytic
therapy.
The role of other MMPs in stroke are not well described
although it also known that MMP-1 (collagenase-1) and MMP-
8 (neutrophil collagenase or collagenase-2) are upregulated in the
infarcted tissue in human brain compared to healthy control areas
(Cuadrado et al., 2009). MMP-8 is very similar to MMP-1 in struc-
ture and physiological function, although subtle differences in
substrate selectivity exist. MMP-8 has a stronger affinity toward
type I collagen than MMP-1, while MMP-1 preferentially cleaves
types III collagen (Balbin et al., 1998). Additional studies examin-
ing the role of MMP-1 and MMP-8, and other MMPs in stroke are
clearly warranted.
MMPs AND tPA-INDUCED REPERFUSION INJURY
For acute ischemic stroke, thrombolysis is beneficial for patients
if induced during the first 3–4.5 h of symptom onset (NINDS,
ECASS III) (National Institute of Neurological Disorders and
Stroke rt-PA Stroke Study Group, 1995; Hacke et al., 2008). Dur-
ing this time window, thrombolysis of the occluded vessel should
rescue the affected ischemic zone and improve clinical outcome.
However, delayed tPA actually increases the risk of disrupting BBB
integrity through changes in the cerebrovasculature. Thrombolytic
tPA then can cross into the perivascular tissue and interact with
the neurovascular unit (Adibhatla and Hatcher, 2008; Niego et al.,
2012). Recent animal model studies of transient and permanent
MCAO demonstrate that genetic deficiency or inhibition of tPA
activity by neuroserpin decrease BBB disruption, edema, neuronal
death, as well as improve stroke outcome (Wang et al., 1998; Tsuji
et al., 2005). Furthermore, examination of both tPA KO and WT
mice demonstrates that endogenous tPA is both necessary and suf-
ficient to induce opening of the BBB after transient MCAO (Yepes
et al., 2003).
The mechanism of vascular unit disruption after ischemia
and reperfusion with tPA has been extensively studied. In part
the disruption may result from the activation of platelet derived
growth factor (PDGF)-CC, a newly discovered PDGF isoform.
tPA increases BBB permeability through PDGF-CC, a known ago-
nist of PDGF-α signaling. To determine whether MCAO-induced
activation of PDGF-α regulates the cerebrovascular response to
stroke, mice were treated with the PDGF-α inhibitor imatinib
mesylate, also known as Gleevec or STI571, 1 h after MCAO (Su
et al., 2008) (Table 2). Animals treated with imatinib exhibited
a 33% reduction in Evans-Blue extravasation after MCAO com-
pared to control mice. In addition, imatinib significantly reduced
hemorrhagic complications when administered 1 h after the onset
of ischemia. Treatment with neutralizing antibodies to PDGF-CC
also reduced Evans-Blue extravasation.
In a separate study reported in this paper, treatment with
tPA significantly increased cerebrovascular permeability, and co-
injection of neutralizing antibodies to PDGF-CC with tPA blocked
the increased permeability suggesting that PDGF-CC is a down-
stream substrate of tPA. Understanding this mechanism offers an
opportunity to potentially extend the treatment window of tPA for
stroke patients. Since blocking the PDGF-CC/PDGFR-α pathway
is unlikely to disrupt tPA’s fibrinolytic function, strategies specifi-
cally targeting the PDGF-CC/PDGFR-α pathway should maintain
tPA’s beneficial thrombolytic activity while minimizing BBB dys-
function. Further studies are needed to determine whether late
administration of a combination therapy of Imatinib plus tPA can
extend the standard 3 h treatment window of tPA, by reducing
hemorrhagic complications and restoring neuroprotection.
Studies in experimental animal models and stroke patients
strongly suggest that MMP-9 plays a central role in tPA-mediated
neurotoxicity from thrombolytic therapy for acute stroke (del
Zoppo, 1995; Lapchak et al., 2000; Sumii and Lo, 2002; Montaner
et al., 2003; Rosell and Lo, 2008). Activated MMP-9 degrades the
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neurovascular matrix (Asahi et al., 2001b), and tPA amplifies total
levels of MMP-9 after ischemia (Sumii and Lo, 2002; Wang et al.,
2003). MMP-9 is expressed in acute ischemic stroke and upregu-
lated by tPA in animal models. Intravenous tPA increased MMP-9
levels in ischemic brains in rats after transient MCAO (Yepes et al.,
2003). Perfusion of tPA resulted in BBB disruption and degrada-
tion of the basal membrane protein, laminin, in rat blood vessels
(Goto et al., 2007). In addition, MMP-9 expression, infarct size,
and brain edema in tPA KO mouse were significantly lower than
in WT mice, indicating that tPA can strongly increase the activity
of MMP-9 in the brain (Tsuji et al., 2005).
Clinical data have also shown that plasma and brain levels of
MMP-9 are elevated in patients with acute ischemic stroke, and
delayed tPA therapy causes a further increase in plasma MMP-
9 in stroke patients (Horstmann et al., 2003; Montaner et al.,
2003; Rosell et al., 2006; Castellanos et al., 2007; Kelly et al., 2008;
Rosell and Lo, 2008; Barr et al., 2010). tPA therapy independently
predicted hyperacute plasma MMP-9 after adjustment for stroke
severity, volume, and HT in the first 8 h after human ischemic
stroke. Hyperacute MMP-9 was correlated with poor 3-month
outcome (Ning et al., 2006). Thus, MMP-9 may be an important
mediator of HT. Alternative thrombolytic agents or therapeutic
inhibition of MMP-9 may increase the safety profile of acute stroke
thrombolysis.
Several potential drugs for reducing tPA-related hemorrhagic
complications have been identified. Many involve protection of the
ECs, at least in part, via inhibition of MMP-9 activity (Table 2).
Minocycline, a highly lipophilic semi-synthetic derivative of the
tetracycline group of antibiotics that is capable of crossing the
BBB, has been found to be a potent MMP inhibitor (Lee et al.,
2006; Machado et al., 2006). In a rat model of embolic focal
cerebral ischemia, minocycline alone effectively decreased infarct
volume by about 25% (Murata et al., 2008). The combination of
minocycline plus 6 h delayed tPA treatment, which by itself was
not protective, reduced infarct volumes by about 50%. In addi-
tion, combination therapy with minocycline can suppress plasma
levels of MMP-9 after ischemic stroke. Importantly, minocycline
can lower plasma MMP-9 levels, even at 72 h after stroke, and
improve neurological outcomes in acute ischemic stroke patients
treated with tPA (Switzer et al., 2011). Thus, adding minocycline
to delayed 6-h tPA therapy produced further benefit.
Besides its effects on infarction, minocycline may also amelio-
rate hemorrhage. Thrombolysis with tPA can elevate the risks of
intracranial hemorrhage after ischemic stroke (National Institute
of Neurological Disorders and Stroke t-PA Stroke Study Group,
1997; Larrue et al., 1999). HT occurs more frequently in patients
receiving treatment at least 6 h after symptom onset (del Zoppo
et al., 1992). Murata et al. (2008) determined whether minocy-
cline can prevent tPA-associated cerebral hemorrhage and extend
the reperfusion window in an experimental stroke model in rats.
In this study, delayed treatment with tPA at 6 h worsened hem-
orrhagic conversion compared with saline and 1-h tPA; however,
combining minocycline with delayed 6-h tPA decreased plasma
MMP-9 levels, reduced infarction, and ameliorated brain hemor-
rhage. Blood levels of MMP-9 were also significantly correlated
with volumes of infarction and hemorrhage. These findings sug-
gest that minocycline may extend the therapeutic time window
of tPA therapy in stroke. The translational attractiveness of this
approach lies in the fact that minocycline is a relatively safe drug
that can be easily used in stroke patients. Recently, it was reported
in a randomized single-blinded open-label study that patients with
acute ischemic stroke had significantly better outcome at day 30
and 90 with oral minocycline treatment as compared with those
administered placebo (Padma Srivastava et al., 2012). These find-
ings suggest that minocycline can be helpful in reducing the clinical
deficits after acute ischemic stroke.
GM6001 is a broad-spectrum MMP inhibitor that provides
protection against hemorrhagic complications induced by tPA
(Table 2) (Mishiro et al., 2012). In mice subjected to 6 h MCAO
with vehicle, delayed tPA alone, or combined tPA plus GM6001,
GM6001 significantly reduced tPA-elevated brain hemoglobin,
MMP-9 activity, and inhibited the degradation of occludin and
ZO-1 induced by tPA, but not claudin-5. Treatment with GM6001
also significantly prevented the decrease in survival rate and the
reduction in locomotor activity caused by tPA at 7 days after
ischemia/reperfusion.
p-aminobenzoyl-gly-pro-d-leu-d-ala-hydroxamate (AHA) is
another broad-spectrum MMP inhibitor that inhibits intersti-
tial collagenases, gelatinases, and stromelysin with IC50 values
of 1, 30, and 150µM, respectively. AHA inhibition 3 h after
MCAO in rats decreased the degree of brain edema, reduced the
risk and gravity of ICH, and improved neurological outcome at
24 h (Table 2) (Copin et al., 2008). The treatment benefit was
decreased if the MMP inhibition was delayed to 6 h post-ischemia,
and this ameliorated the reduction in parenchymal hemorrhage.
These results confirm the involvement of MMPs in HT and sup-
port the possibility of extending the window for thrombolysis in
stroke by administering a broad-spectrum MMP inhibitor after
ischemia.
Activated protein C (APC) is a vitamin K-dependent serine
protease that inhibits blood clotting in plasma (Rezaie, 2003). It is
activated from the circulating protein C zymogen on the surface
of ECs. Cheng et al. (2006) reported that APC could inhibit tPA-
induced hemorrhage in the ischemic rat brain (Table 2). Moreover,
this effect was accompanied by inhibition of MMP-9 activity. The
inhibition was absent in protease-activated receptor 1 (PAR1)
KO mouse, indicating that PAR1 is required for APC-mediated
down-regulation of tPA-induced MMP-9 (Cheng et al., 2006). At
present, APC is not available to treat patients with ischemic stroke;
however, human recombinant APC [drotrecogin alfa (activated)]
was approved by the FDA for the treatment of severe sepsis or
septic shock (Casserly et al., 2012). A modified APC, designed
to possess significantly reduced coagulant activity (<10%) while
maintaining full cytoprotective properties, is currently in pre-
clinical development, and based upon the anticoagulant profiles,
makes this new drug a feasible therapy for ischemic stroke patients
(Williams et al., 2012).
Cilostazol, a selective inhibitor of phosphodiesterase III, is an
antiplatelet drug and vasodilator via increased levels of cyclic
AMP (cAMP) and cyclic GMP (Tanaka et al., 1989). Researchers
have reported that cilostazol has a neuroprotective effect against
ischemic brain injury induced by MCAO and reperfusion in rats
(Choi et al., 2002; Lee et al., 2003). In addition, cilostazol prevented
the HT induced by tPA and reduced the hemoglobin content
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and water content, as well as the MMP-9 activity in mice sub-
jected to MCAO and reperfusion (Table 2) (Ishiguro et al., 2010).
Cilostazol also prevented the decrease in claudin-5 expression,
which is altered by tPA, and inhibited tPA-induced cell damage
in human BMECs. This supports the idea that cilostazol lim-
its or prevents BBB disruption after ischemic injury. The loss of
claudin-5 and activation of MMP-9 were found in CD47 KO mice,
indicating CD47 contributes to the disruption of BBB through
activating MMP-9 (Jin et al., 2009). Thus, cilostazol could be used
to downregulate the overall inflammatory MMP-9 response and
upregulate claudin-5. Similar results were obtained with the Rho
kinase (ROCK) inhibitor, fasudil, which was also shown to prevent
MMP-9-related HT in mice treated with tPA (Table 2) (Ishiguro
et al., 2012).
Matrix metalloproteinase-9 can be activated by tPA via sev-
eral molecular signaling pathways, including the tPA-LRP and
tPA-PAR1 pathways. tPA stimulates MMP-9 expression in brain
ECs. This effect is significantly reduced in cells treated with RNAi
against LRP, and was absent in LRP-deficient mouse embryonic
fibroblast cells (Wang et al., 2003). Moreover, intraventricular
injection of tPA into the mouse brain increased BBB permeabil-
ity, although LRP antagonists blocked this effect. These findings
indicate that LRP signaling pathways play an important role in
tPA-induced MMP-9 activation.
In spite of the strong evidence for the role of MMP-9 in the dele-
terious effects of tPA, tPA toxicity could involve some other MMPs.
In a recent study (Copin et al., 2011), WT and MMP-9 KO mice
were subjected to 90 min transient MCAO and treated with tPA.
At 24 h after occlusion, BBB permeability, hemispheric enlarge-
ment, collagen and laminin degradation, and cerebral infarction
were increased in both WT and MMP-9 KO treated animals as
compared with non-treated animals. Mortality was increased in
WT but reduced in KO treated mice. Cerebral MMP-9 concentra-
tion was not modified by tPA. However, pre-treatment with the
MMP broad-spectrum inhibitor AHA counteracted the effects of
tPA on the neurovascular unit and decreased mortality in both WT
and KO mice. MMP inhibition did not modify cerebral infarction
in tPA-treated animals. These results suggest that tPA toxicity is
mainly independent of MMP-9 after transient MCAO but could
involve some other MMPs. This represents a substantial shift
from the previous focus on MMP-9/BBB breakdown and the role
of tPA.
Tissue plasminogen activator induces the activity of other
MMPs, in addition to MMP-9. In vitro, tPA induces MMP-3 in
cultured murine brain ECs, and this effect is prevented by inhibi-
tion of either LRP or the NF-κB activation (Suzuki et al., 2009). The
involvement of the LRP/NF-κB pathway was also reported in the
induction of MMP-3 by tPA under ischemic stress. In addition, the
increase in both ICH and the induction of MMP-3 by tPA was sup-
pressed by treatment with RAP, suggesting that ICH caused by tPA
could be suppressed by LRP inhibition. These results support the
hypothesis of dissociation between tPA-dependent mechanisms of
BBB breakdown and cerebral infarction. Due to the importance of
tPA in thrombolytic treatment of ischemic stroke patients, further
characterization of the MMPs participating in tPA-induced BBB
disruption could be clinically useful.
OXIDATIVE STRESS AND MMPs
There is a strong association between oxidative stress and MMPs
in the pathophysiology of BBB damage and ischemic stroke.
Oxidative stress is defined as the condition occurring when the
physiological balance between oxidants and antioxidants is tipped
in favor of the oxidants, increasing the risk for potential dam-
age to the organism. Free radicals, including ROS and reactive
nitrogen species (RNS), are generated soon after vessel occlu-
sion (Lapchak et al., 2000). Accumulated free radicals not only
increase the susceptibility of brain tissue to ischemic damage, but
also trigger numerous molecular cascades that mediate the activa-
tion of MMPs. This leads to degradation of TJs and increased BBB
permeability in the ischemic brain (Lijnen, 2001).
Elevated levels of RNS and tyrosine nitration were observed
in brain sections of stroke patients and in experimental ischemic
animal models (Lijnen and Collen, 1987; National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study Group,
1995; Miller et al., 2012; Wardlaw et al., 2012). Moreover, super-
oxide scavengers, nitric oxide synthase (NOS) inhibitors, and
peroxynitrite decomposition catalysts attenuated BBB disruption,
reduced infarction volume, and improved neurological dysfunc-
tions in cerebral I/R injury. Superoxide dismutase (SOD2) is the
principal defense against the toxicity of free radicals, which leads
SOD2 KO mice to exhibit a significant increase in MMP-9 and
a higher rate of brain hemorrhaging after MCAO (Maier et al.,
2006). This indicates that the excess radicals can activate MMP-9,
thereby inducing HT in the post-ischemic brain. These findings
suggest that free radicals are an important therapeutic target for
improving the outcome of an ischemic stroke.
Experimental data indicate that oxidative stress may be an early
trigger of MMP upregulation after cerebral ischemia-reperfusion
(Asahi et al., 2000a; Gasche et al., 2001; Liu and Rosenberg, 2005).
Using human BMECs grown on porous membranes covered with
BM matrix (BBB models), it was shown that ROS augmented
permeability and monocyte migration across the BBB. ROS acti-
vated MMPs (MMP-1, -2, and -9) and decreased tissue inhibitors
of MMPs (TIMP-1 and -2) in a protein tyrosine kinase (PTK)-
dependent manner. In addition, the increase in MMPs and PTK
activities paralleled degradation of BM protein and enhanced tyro-
sine phosphorylation of TJ protein. These effects and enhanced
permeability/monocyte migration were prevented by inhibitors
of MMPs or PTKs, or antioxidant therapy. The findings suggest
that oxidative stress causes BBB injury via degradation of BM
proteins by activated MMPs and by PTK-mediated TJ protein
phosphorylation.
Reactive oxygen species and its signaling pathways can enhance
tPA-mediated MMP-9 production (Harada et al., 2012). Using
cultured brain ECs (b.End3) exposed to tPA, followed by H2O2,
Harada et al. showed that the combination of ROS and tPA sig-
nificantly increased MMP-9 production more than tPA or ROS
alone. Moreover, this MMP-9 production was decreased by the
addition of the free radical scavenger edaravone (MCI-186, 3-
methyl-1-phenyl-2-pyrazoline-5-one), which inhibited the NF-
κB pathway, specifically by enhancing I-κB degradation (Harada
et al., 2012). Edaravone suppresses tPA-induced MMP-9 upreg-
ulation and hemorrhage in the transiently ischemic rat brain
Frontiers in Neurology | Stroke April 2013 | Volume 4 | Article 32 | 10
Lakhan et al. Matrix metalloproteinases in ischemic stroke
(Yagi et al., 2008). In a spontaneously hypertensive rat model
of MCAO, administration of edaravone plus tPA increased sur-
vival rate, improved motor function, and dramatically decreased
tPA-induced HT (Table 2) (Yamashita et al., 2011). In addition,
edaravone suppressed MMP-9 expression at and around cere-
bral microvessels, inhibited the degradation of BM protein, and
prevented the microvessels from dissociating. These results sug-
gest that edaravone could protect the cerebral microvasculature
because it safeguards the BM from excess free radicals and MMP-
9. Thus, edaravone may provide effective neuroprotection, prevent
vascular endothelial injury, and delay neuronal death in transient
cerebral ischemia and ischemic stroke.
Edaravone has been used clinically in Japan and shown to be
efficacious in patients with acute ischemic stroke (Suda et al., 2007)
(Table 2). Edaravone also improved the functional outcome in
a group of Indian patients with acute ischemic stroke (Sharma
et al., 2011). In addition, administration of edaravone during tPA
infusion can enhance early recanalization in acute stroke patients
(Kimura et al., 2012). In a large clinical trial, another free radi-
cal scavenger, NXY-059 also reduced tPA-induced HT in humans
(Table 2) (Lees et al., 2006); however, it failed to reduce dis-
ability after stroke in a subsequent trial (Shuaib et al., 2007).
The clinical efficacy of NXY-059 may be limited by its reduced
ability to penetrate the BBB and its restricted radical trapping
capacity (Murata et al., 2008). Nevertheless, combination therapy
with edaravone and tPA is a promising therapeutic strategy for
acute stroke patients, not only in reducing infarct size but also in
minimizing catastrophic HT.
MMPs AND CAVEOLIN-1
Caveolae are small invaginations of the plasma membrane that
form flask-like structures in many vertebrate cells, especially ECs.
There are three members in the caveolin (cav) family: cav-1, 2, and
3. Cav-1 appears to be a critical determinant of BBB permeability
(Gu et al., 2011). Recent studies revealed that cav-1 could prevent
the degradation of TJ proteins and protect the BBB integrity by
inhibiting RNS production and MMP activity. In addition, cav-1
KO mice had higher rates of apoptotic cell death and larger infarc-
tion volumes than WT mice in an experimental ischemic stroke
model. Current evidence indicates that the interactions of RNS,
cav-1, and MMPs are critical signal pathways in BBB disruption
and infarction enlargement during cerebral ischemia-reperfusion
injury (Gu et al., 2011).
Expression of cav-1 was down regulated in ischemic brains
and the production of NO induced the loss of cav-1 in focal
cerebral ischemia and reperfusion injury (Gu et al., 2012). The
down-regulation of cav-1 was correlated with increased MMP-
2 and -9 activities, decreased ZO-1 expression, and enhanced
BBB permeability. Treatment with N(G) -nitro-l-arginine methyl
ester (l-NAME, a non-selective NOS inhibitor) preserved the
expression of cav-1, inhibited MMPs activity, and reduced BBB
permeability.
To elucidate the roles of cav-1 in regulating MMPs and BBB
permeability, Gu et al. (2012) used two approaches including cav-
1 knock down in cultured BMECs in vitro and cav-1 KO mice
in vivo. Cav-1 knock down remarkably increased MMPs activity in
BMECs. Meanwhile, with focal cerebral ischemia-reperfusion, cav-
1KO mice displayed higher MMPs activities and BBB permeability
than WT mice. The effects of l-NAME on MMPs activity and BBB
permeability were partly reversed in cav-1 deficient mice. These
results, when taken together, suggest that cav-1 plays important
roles in regulating MMPs activity and BBB permeability in focal
cerebral ischemia and reperfusion injury. The effects of l-NAME
on MMPs activity and BBB permeability are partly mediated by
preservation of cav-1.
There is also suggestive evidence that cav-1 might at least par-
tially regulate some endothelial TJ proteins by controlling their
degradation by MMPs. Liu et al. (2012) investigated the early mole-
cular events of ischemic BBB damage using in vitro oxygen-glucose
deprivation (OGD) and in vivo rat MCAO models. Exposure of
bEND3 monolayer to OGD for 2 h significantly increased its per-
meability to FITC-labeled dextran and promoted the secretion of
MMP-2/-9 and cytosolic translocation of cav-1. This same OGD
treatment also led to rapid degradation of TJ protein occludin
and dissociation of claudin-5 from the cytoskeleton, which con-
tributed to OGD-induced endothelial barrier disruption. Using
the selective MMP-2/-9 inhibitor SB-3CT, their neutralizing anti-
bodies, or cav-1 siRNA, the investigators found that MMP-2 was
the major enzyme mediating OGD-induced occludin degrada-
tion, while cav-1 was responsible for claudin-5 redistribution. The
interaction between cav-1 and claudin-5 was further confirmed
by co-immunoprecipitation. Consistent with these in vitro find-
ings, the researchers observed fluorescence tracer extravasation,
increased gelatinolytic activity, and elevated interstitial MMP-2
levels in ischemic subcortical tissue after 2 h MCAO. Moreover,
occludin protein loss and claudin-5 redistribution were detected
in ischemic cerebromicrovessels. These data indicate that cerebral
ischemia initiates two rapid parallel processes, MMP-2-mediated
occludin degradation and cav-1-mediated claudin-5 redistribu-
tion, causing BBB disruption at early stroke stages. These parallel
processes are relevant to the process of acute thrombolysis.
CONCLUSION
Blood-brain barrier dysfunction is a critical pathophysiological
process in stroke and occurs early enough to be within the throm-
bolytic time window. This early ischemic BBB damage is closely
associated with HT and thus is emerging as a promising target for
reducing the hemorrhagic complications of thrombolytic stroke
therapy. However, the mechanisms underlying early ischemic BBB
damage remain poorly understood. Understanding the exact role
of MMPs and its signal cascades after ischemic stroke will have
important diagnostic implications for stroke and for the devel-
opment of therapeutic strategies aimed at modulating MMPs.
Unfortunately, in view of its complex pathophysiology, which
affects blood vessels, neurons, and glial cells, the quick translation
of experimental discoveries into clinical practice has previously
raised problems, and ischemic stroke remains one of the most
challenging diseases in translational neurology. The advances in
our understanding of basic stroke pathophysiology, along with
improvements in the design of our basic and clinical studies,
should make it possible for causative therapeutic strategies to soon
find their way into clinics.
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